Evaluation of the Results of Simultaneous Pancreatic and Hepatic Resections for Metastatic Neuroendocrine Tumors.

NCT05528614 | Completed

• 1 other identifier: 8511
• Study Type: observational
• Target: 51
• Locations: 1 country
• Sites: 1

Brief Summary

The indications for synchronous liver resection for metastatic neuroendocrine tumors of pancreatic origin remain debated and poorly described in the literature. The reported mortality of this type of simultaneous resection remains very high, especially when a cephalic duodenopancreatectomy is associated with a hepatic resection (up to 40%). The benefit in terms of survival remains to be evaluated. The ReSiPaTNE study proposes to create a retrospective cohort of simultaneous pancreatic and hepatic resections for metastatic neuroendocrine tumors in order to evaluate the short and long term results of this type of resection. The evaluation of the results of this type of resection may be useful for the selection of patients for treatment.

Conditions

Tumor of Pancreas

Keywords

Tumor of Pancreas; Metastatic neuroendocrine tumors; Hepatic resection; Pancreatic resection

Outcome Measures

Primary Outcomes (1)

• Postoperative morbidity and mortality of simultaneous pancreatic and hepatic resectio

  Morbidity and mortality at 90 postoperative days

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Major subjects (≥18 years old) having had a first pancreatic resection for NET with resections of synchronous metastases

You may qualify if:

• Major subjects (≥18 years old)
• Subject having had a first pancreatic resection for NET with resections of synchronous metastases
• Subject having had a first pancreatic resection for NET followed by a delayed resection of synchronous metastases
• Subject who has not expressed his opposition, after being informed, to the reuse of his data for the purposes of this research

You may not qualify if:

• Subject who expressed their opposition to participating in the study
• Pregnant women
• Subject under safeguard of justice
• Subjects under guardianship or curatorship

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service de Chirurgie Générale, Hépatique, Endocrinienne et Transplantation - CHU de Strasbourg - France

Strasbourg, 67091, France

Location

MeSH Terms

Conditions

Pancreatic Neoplasms; Neuroendocrine Tumors

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms, Nerve Tissue

Study Officials

• Pietro ADDEO, MD

  Service de Chirurgie Générale, Hépatique, Endocrinienne et Transplantation - CHU de Strasbourg - France

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 29, 2022
• First Posted: September 6, 2022
• Study Start: January 13, 2022
• Primary Completion: November 13, 2022
• Study Completion: January 13, 2023
• Last Updated: November 8, 2023

Record last verified: 2022-08

Locations

FR (1)